Skip to content
Locus Biosciences announces positive results from part 1 of ELIMINATE phase 2 trial of the engineered bacteriophage therapy LBP-EC01 published in The Lancet Infectious Diseases
We use cookies to ensure that we give you the best experience on our website. Please visit carb-x.org/legal/ for more information. By clicking “Ok”, you consent to the use of all cookies.OkI do not consent
Toggle navigation